Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach
Bioorganic & Medicinal Chemistry · 2024
DOI: 10.1016/j.bmc.2024.117633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Feng Gao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd., Shanghai 201203, China. Hauptthemen laut MEDLINE: Methionine Adenosyltransferase, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
The methionine adenosyltransferase MAT2A catalyzes the synthesis ofthe methyl donor S-adenosylmethionine (SAM) and thereby regulates critical aspects of metabolism and transcription. Aberrant MAT2A function can lead to metabolic and transcriptional reprogramming of cancer cells, and MAT2A has been shown to promote survival of MTAP-deficient tumors, a genetic alteration that occurs in ∼ 13 % of all tumors. Thus, MAT2A holds great promise as a novel anticancer target. Here, we report a novel series of MAT2A inhibitors generated by a fragment growing approach from AZ-28, a low-molecular weight MAT2A inhibitor with promising pre-clinical properties. X-ray co-crystal structure revealed that compound 7 fully occupies the allosteric pocket of MAT2A as a single molecule mimicking MAT2B. By introducing additional backbone interactions and rigidifying the requisite linker extensions, we generated compound 8, which exhibited single digit nanomolar enzymatic and sub-micromolar cellular inhibitory potency for MAT2A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Insilico Medicine Shanghai Ltd., Shanghai 201203, China.
- Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong.
- Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.
- Insilico Medicine Shanghai Ltd., Shanghai 201203, China. Electronic address: xiao.ding@insilico.ai.
- Insilico Medicine Shanghai Ltd., Shanghai 201203, China; Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE. Electronic address: alex@insilico.com.
Zitieren
APA
Gao, F., Ding, X., Cao, Z., Zhu, W., Fan, Y., Steurer, B., Wang, H., Cai, X., Zhang, M., Aliper, A., Ren, F., Ding, X., & Zhavoronkov, A. (2024). Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117633
Vancouver
Gao F, Ding X, Cao Z, Zhu W, Fan Y, Steurer B, et al. Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117633
BibTeX
@article{Gao2024,
author = {Gao, Feng and Ding, Xiaoyu and Cao, Zhongying and Zhu, Wei and Fan, Yaya and Steurer, Barbara and Wang, Hailong and Cai, Xin and Zhang, Man and Aliper, Alex and Ren, Feng and Ding, Xiao and Zhavoronkov, Alex},
title = {Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach},
journal = {Bioorganic & Medicinal Chemistry},
year = {2024},
doi = {10.1016/j.bmc.2024.117633}
}
EUVIMED